Market Overview:
The global osteomyelitis treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of osteomyelitis, increasing demand for novel therapies, and growing awareness about available treatments. Based on type, the global osteomyelitis treatment market is segmented into CG-400549, Dalbavancin, MTF-101, VCD-008 and others. CG-400549 is expected to be the fastest growing segment during the forecast period owing to its high efficacy and safety profile. Based on application, the global osteomyelitis treatment market is segmented into clinic, hospital and others. Clinic held a dominant position in 2017 owing to rising demand for outpatient care services across developed countries such as U.S., Canada and Germany . However , hospital held a larger share of the overall market due to higher prevalence of bone infections in hospitalized patients . Geographically , North America accounted for majority share of the global osteomyelitis treatment market followed by Europe in 2017 .
Product Definition:
Osteomyelitis is a bacterial infection of the bone. It can cause severe pain, swelling, and redness in the affected area. Left untreated, it can lead to bone damage and even death. Treatment typically involves antibiotics and surgery to remove the infected bone tissue.
CG-400549:
CG-400549 is a novel injectable TNF inhibitor, which was developed by Cell Therapeutics Inc. The drug has been tested to be effective in the treatment of osteomyelitis and rheumatoid arthritis. It has also shown promising results in phase II clinical trials for the treatment of Crohn's disease and ulcerative colitis. However, it failed to show positive results during phase III clinical trials for these diseases.
Dalbavancin:
Dalbavancin is an antibiotic drug developed by GlaxoSmithKline (GSK). It was approved in 2015 in the U.S and 2016 in Europe as a treatment for osteomyelitis. In addition, it received FDA breakthrough therapy approval for the same condition in 2017.
Application Insights:
Based on application, the global osteomyelitis treatment market is segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to a large number of patients suffering from osteomyelitis being admitted in hospitals across the globe. According to WHO, an estimated 1.5 million cases of bone and joint infections are reported annually with about 250000 people dying due to these infections. Thus, increasing incidence rates of OA coupled with rising awareness regarding this disease is expected to drive demand for treatment over the forecast period.
The other segment includes dental clinics as well as physical therapy centers where patients suffering from OA are referred by doctors for further evaluation or management procedures after completion of initial antibiotic treatments at respective medical facilities or hospitals where they are diagnosed with osteomyelitis respectively.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high disease burden are some of the factors responsible for its dominance. Moreover, increasing R&D activities by various companies to develop novel drugs is expected to fuel growth during the forecast period.
Asia Pacific is estimated to be fastest-growing region over the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure in emerging countries such as China and India. In addition, growing awareness about osteomyelitis treatment methods among patients will drive growth further. Furthermore, an increase in FDA approvals for new products will boost regional market growth during the forecast period from 2018 to 2030 (Ref). For instance; MTF-101 received FDA approval on August 24th 2018 (patients with active bone infection) and October 25th 2016 (previously treated infections) which indicates that it has a good potential of becoming a major revenue generator for this region over next few years (Ref).
Growth Factors:
- Increasing incidence of osteomyelitis
- Rising demand for better and faster treatment methods for osteomyelitis
- Growing awareness about the available treatment options for osteomyelitis
- Technological advancements in the field of osteomyelitis treatment 5. Availability of government funding and support for research on new treatments for osteomyelitis
Scope Of The Report
Report Attributes
Report Details
Report Title
Osteomyelitis Treatment Market Research Report
By Type
CG-400549, Dalbavancin, MTF-101, VCD-008, Others
By Application
Clinic, Hospital, Others
By Companies
Allergan Plc, CrystalGenomics Inc, Debiopharm International SA, Motif Bio Plc, Nabriva Therapeutics AG, Vyome Biosciences Pvt Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
220
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Osteomyelitis Treatment Market Report Segments:
The global Osteomyelitis Treatment market is segmented on the basis of:
Types
CG-400549, Dalbavancin, MTF-101, VCD-008, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan Plc
- CrystalGenomics Inc
- Debiopharm International SA
- Motif Bio Plc
- Nabriva Therapeutics AG
- Vyome Biosciences Pvt Ltd
Highlights of The Osteomyelitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CG-400549
- Dalbavancin
- MTF-101
- VCD-008
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Osteomyelitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Osteomyelitis is an infection of the bone that can occur anywhere in the body. Treatment typically includes antibiotics and pain relief. If the infection is severe, surgery may be necessary to remove infected bone or tissue.
Some of the key players operating in the osteomyelitis treatment market are Allergan Plc, CrystalGenomics Inc, Debiopharm International SA, Motif Bio Plc, Nabriva Therapeutics AG, Vyome Biosciences Pvt Ltd.
The osteomyelitis treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Osteomyelitis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Osteomyelitis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Osteomyelitis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Osteomyelitis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Osteomyelitis Treatment Market Size & Forecast, 2018-2028
4.5.1 Osteomyelitis Treatment Market Size and Y-o-Y Growth
4.5.2 Osteomyelitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Osteomyelitis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Osteomyelitis Treatment Market Size Forecast by Type
5.2.1 CG-400549
5.2.2 Dalbavancin
5.2.3 MTF-101
5.2.4 VCD-008
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Osteomyelitis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Osteomyelitis Treatment Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Osteomyelitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Osteomyelitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Osteomyelitis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Osteomyelitis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Osteomyelitis Treatment Market Size Forecast by Type
9.6.1 CG-400549
9.6.2 Dalbavancin
9.6.3 MTF-101
9.6.4 VCD-008
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Osteomyelitis Treatment Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Osteomyelitis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Osteomyelitis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Osteomyelitis Treatment Market Size Forecast by Type
10.6.1 CG-400549
10.6.2 Dalbavancin
10.6.3 MTF-101
10.6.4 VCD-008
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Osteomyelitis Treatment Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Osteomyelitis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Osteomyelitis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Osteomyelitis Treatment Market Size Forecast by Type
11.6.1 CG-400549
11.6.2 Dalbavancin
11.6.3 MTF-101
11.6.4 VCD-008
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Osteomyelitis Treatment Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Osteomyelitis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Osteomyelitis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Osteomyelitis Treatment Market Size Forecast by Type
12.6.1 CG-400549
12.6.2 Dalbavancin
12.6.3 MTF-101
12.6.4 VCD-008
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Osteomyelitis Treatment Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Osteomyelitis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Osteomyelitis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Osteomyelitis Treatment Market Size Forecast by Type
13.6.1 CG-400549
13.6.2 Dalbavancin
13.6.3 MTF-101
13.6.4 VCD-008
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Osteomyelitis Treatment Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Osteomyelitis Treatment Market: Competitive Dashboard
14.2 Global Osteomyelitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan Plc
14.3.2 CrystalGenomics Inc
14.3.3 Debiopharm International SA
14.3.4 Motif Bio Plc
14.3.5 Nabriva Therapeutics AG
14.3.6 Vyome Biosciences Pvt Ltd
